WO2023194839A1 - Fenêtre de schéma thérapeutique cutané d'opportunité et composition pour prévenir l'apparition de la dermatite atopique ou pour traiter celle-ci - Google Patents

Fenêtre de schéma thérapeutique cutané d'opportunité et composition pour prévenir l'apparition de la dermatite atopique ou pour traiter celle-ci Download PDF

Info

Publication number
WO2023194839A1
WO2023194839A1 PCT/IB2023/052887 IB2023052887W WO2023194839A1 WO 2023194839 A1 WO2023194839 A1 WO 2023194839A1 IB 2023052887 W IB2023052887 W IB 2023052887W WO 2023194839 A1 WO2023194839 A1 WO 2023194839A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
skin
regimen
opportunity
window
Prior art date
Application number
PCT/IB2023/052887
Other languages
English (en)
Inventor
Thierry Oddos
Georgios N. Stamatas
Catherine Coret
Jonathan HOURIHANE
Alan D. IRVINE
Original Assignee
Donnelly
University College Cork
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US18/124,977 external-priority patent/US20230309921A1/en
Application filed by Donnelly, University College Cork filed Critical Donnelly
Publication of WO2023194839A1 publication Critical patent/WO2023194839A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation

Abstract

L'invention concerne une fenêtre de schéma thérapeutique cutané d'opportunité et une composition destinés à prévenir l'apparition de la dermatite atopique ou à la traiter.
PCT/IB2023/052887 2022-04-04 2023-03-23 Fenêtre de schéma thérapeutique cutané d'opportunité et composition pour prévenir l'apparition de la dermatite atopique ou pour traiter celle-ci WO2023194839A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202263327052P 2022-04-04 2022-04-04
US63/327,052 2022-04-04
US18/124,977 US20230309921A1 (en) 2022-04-04 2023-03-22 Window of Opportunity Skin Treatment Regimen and Composition for Preventing the Onset of or Treating Atopic Dermatitis
US18/124,977 2023-03-22

Publications (1)

Publication Number Publication Date
WO2023194839A1 true WO2023194839A1 (fr) 2023-10-12

Family

ID=85979609

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2023/052887 WO2023194839A1 (fr) 2022-04-04 2023-03-23 Fenêtre de schéma thérapeutique cutané d'opportunité et composition pour prévenir l'apparition de la dermatite atopique ou pour traiter celle-ci

Country Status (1)

Country Link
WO (1) WO2023194839A1 (fr)

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020182112A1 (en) 2001-04-30 2002-12-05 Unilever Home & Personal Care Usa, Division Of Conopco, Inc. In vivo method for measuring binding of chemical actives to skin or specific constituents of skin
US20100016232A1 (en) 2008-07-18 2010-01-21 Novozymes A/S Treatment Of Inflammatory Diseases With Mammal Beta Defensins
US20110217249A1 (en) 2010-03-03 2011-09-08 Frank Dreher Compositions and Methods for the Treatment of Skin Diseases and Disorders Using Antimicrobial Peptide Sequestering Compounds
US8053003B2 (en) 1999-09-22 2011-11-08 Laboratoires Expanscience Use of a plant oil product as an agent for increasing the synthesis of skin lipids
WO2017009364A1 (fr) * 2015-07-14 2017-01-19 Swecure Ab Réduction du risque de développement d'une dermatite atopique par utilisation d'un super-antigène
US9808408B2 (en) 2010-01-17 2017-11-07 The Procter & Gamble Company Biomarker-based methods for formulating compositions that improve skin quality and reduce the visible signs of aging in skin for individuals in a selected population
US10175230B2 (en) 2013-04-19 2019-01-08 Laboratoires Expanscience Use of biomarkers for evaluating the effectiveness of active ingredients
US10226499B2 (en) 2010-12-28 2019-03-12 Kamedis Ltd. Plant extracts for the treatment and prevention of infections
US20190242880A1 (en) 2015-12-16 2019-08-08 Laboratoires Expanscience Method for evaluating the effects of dehydration on children's skin
US20200360259A1 (en) 2019-05-15 2020-11-19 Johnson & Johnson Consumer Inc. Method of Selecting Skin Treatment Regimens, Ingredients and Compositions
US11090393B2 (en) 2018-01-05 2021-08-17 Johnson & Johnson Consumer Inc. Mild surfactant preparation and method therefor
US11229595B2 (en) 2019-05-29 2022-01-25 Johnson & Johnson Consumer Inc. Skin barrier preparation and method therefor

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8053003B2 (en) 1999-09-22 2011-11-08 Laboratoires Expanscience Use of a plant oil product as an agent for increasing the synthesis of skin lipids
US20020182112A1 (en) 2001-04-30 2002-12-05 Unilever Home & Personal Care Usa, Division Of Conopco, Inc. In vivo method for measuring binding of chemical actives to skin or specific constituents of skin
US20100016232A1 (en) 2008-07-18 2010-01-21 Novozymes A/S Treatment Of Inflammatory Diseases With Mammal Beta Defensins
US10172771B2 (en) 2010-01-17 2019-01-08 The Procter & Gamble Company Biomarker-based methods for formulating compositions that improve skin quality and reduce the visible signs of aging in skin for individuals in a selected population
US9808408B2 (en) 2010-01-17 2017-11-07 The Procter & Gamble Company Biomarker-based methods for formulating compositions that improve skin quality and reduce the visible signs of aging in skin for individuals in a selected population
US20110217249A1 (en) 2010-03-03 2011-09-08 Frank Dreher Compositions and Methods for the Treatment of Skin Diseases and Disorders Using Antimicrobial Peptide Sequestering Compounds
US10226499B2 (en) 2010-12-28 2019-03-12 Kamedis Ltd. Plant extracts for the treatment and prevention of infections
US10175230B2 (en) 2013-04-19 2019-01-08 Laboratoires Expanscience Use of biomarkers for evaluating the effectiveness of active ingredients
WO2017009364A1 (fr) * 2015-07-14 2017-01-19 Swecure Ab Réduction du risque de développement d'une dermatite atopique par utilisation d'un super-antigène
US20190242880A1 (en) 2015-12-16 2019-08-08 Laboratoires Expanscience Method for evaluating the effects of dehydration on children's skin
US11090393B2 (en) 2018-01-05 2021-08-17 Johnson & Johnson Consumer Inc. Mild surfactant preparation and method therefor
US20200360259A1 (en) 2019-05-15 2020-11-19 Johnson & Johnson Consumer Inc. Method of Selecting Skin Treatment Regimens, Ingredients and Compositions
US11229595B2 (en) 2019-05-29 2022-01-25 Johnson & Johnson Consumer Inc. Skin barrier preparation and method therefor

Non-Patent Citations (36)

* Cited by examiner, † Cited by third party
Title
"Skin barrier dysfunction measured by transepidermal water loss (TEWL) at 2 days and 2 months predates and predicts atopic dermatitis at 1 year", J ALLERGY CLIN IMMUNOL 2015, vol. 135, no. 4, pages 930 - 935
ALMOSE ET AL.: "Non-invasive assessment of soluble skin surface biomarkers in atopic dermatitis patients-Effect of treatment.", SKIN RESEARCH AND TECHNOLOGY, 2021
ANONYMOUS: "Short-term Topical Application to Prevent Atopic Dermatitis - Full Text View - ClinicalTrials.gov", 12 March 2019 (2019-03-12), XP093055808, Retrieved from the Internet <URL:https://clinicaltrials.gov/ct2/show/NCT03871998> [retrieved on 20230620] *
BIEBER: "22", ANN DERMATOL, no. 2, 2010, pages 125 - 137
BROSS IDJ: "Foundations of Statistical Inference", 1971, RINEHART & WINSTON OF CANADA, LTD, article "Critical Levels, Statistical Language and Scientific Inference"
CAPONE ET AL., EFFECTS OF EMOLLIENT USE ON THE DEVELOPING SKIN MICROBIOME, PRESENTED AT THE AMERICAN ACADEMY OF DERMATOLOGY ANNUAL MEETING, 1-5 MARCH 2019, WASHINGTON DC, USA, 1 March 2019 (2019-03-01)
CAPONE ET AL.: "Effects of emollient use on the developing skin microbiome", AMERICAN ACADEMY OF DERMATOLOGY ANNUAL MEETING, 1-5 MARCH 2019, WASHINGTON DC, USA, 1 March 2019 (2019-03-01)
CHALMERS JRHAINES RHBRADSHAW LEMONTGOMERY AATHOMAS KSBROWN SJRIDD MJLAWTON SSIMPSON ELCORK MJ ET AL.: "Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial", LANCET 2020, vol. 395, no. 10228, 2020, pages 962 - 972, XP086100141, DOI: 10.1016/S0140-6736(19)32984-8
CHAMBERS ET AL.: "Daily emollient during infancy for prevention of eczema: the BEEP randomized controlled trial", LANCET 2020, vol. 395, 19 February 2020 (2020-02-19), pages 962 - 72, XP086100141, DOI: 10.1016/S0140-6736(19)32984-8
CHIOU ET AL., SKIN PHARMACOL PHYSIOL, vol. 17, 2004, pages 57 - 66
EICHENFIELD ET AL., J AM ACAD DERMATOL, vol. 71, no. 1, 2014, pages 116 - 132
FLUHR ET AL., BR J DERMATOL, vol. 166, no. 3, 2012, pages 483 - 90
FLUHR ET AL., BR J DERMATOL, vol. 171, no. 5, 2014, pages 978 - 86
GLATZ ET AL.: "Emollient use alters skin barrier and microbes in infants at risk for developing atopic dermatitis", PLOS ONE, vol. 13, no. 2, 2018, pages e0192443
HANIFIN ET AL.: "Guidelines of care for atopic dermatitis", J AM ACAD DERMATOL, 2004
HORIMUKAI KENTA ET AL: "Application of moisturizer to neonates prevents development of atopic dermatitis", JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, vol. 134, no. 4, 1 October 2014 (2014-10-01), AMSTERDAM, NL, pages 824 - 830.e6, XP093055791, ISSN: 0091-6749, DOI: 10.1016/j.jaci.2014.07.060 *
HORIMUKAI KMORITA KNARITA MKONDO MKITAZAWA HNOZAKI MSHIGEMATSU YYOSHIDA KNIIZEKI HMOTOMURA KET: "Application of moisturizer to neonates prevents the development of atopic dermatitis", J ALLERGY CLIN IMMUNOL 2014, vol. 134, no. 4, pages 824 - 30
KELLEHER ET AL.: "Cochrane database of systemic reviews", 2021, JOHN WILEY & SONS, LTD., article "Skin care interventions in infants for preventing eczema and food allergy (review"
KELLEHER MMDUNN-GALVIN AGRAY CMURRAY DMKIELY MKENNY LMCLEAN WHIIRVINE AD: "Hourihane JO'BH. Skin barrier impairment at birth predicts food allergy at 2 years of age", J ALLERGY CLIN IMMUNOL, vol. 137, no. 4, 2016, pages 1111 - 6
LAD ET AL.: "Neonatal natural moisturizing factor concentrations in a high-risk cohort with parental history of atopy compared to a reference cohort", EUROPEAN ACADEMY OF ALLERGY AND CLINICAL IMMUNOLOGY (EAACI) 2020, 2020
LOWE AJ ET AL.: "A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitization: the PEBBLES pilot study", BMC DERMATOL, vol. 178, no. 1, 2018, pages e19 - e21, XP071132116, DOI: 10.1111/bjd.15747
NÍ CHAOIMH CAROL ET AL: "Early initiation of short-term emollient use for the prevention of atopic dermatitis in high-risk infants-The STOP-AD randomised controlled trial", ALLERGY, vol. 78, no. 4, 8 September 2022 (2022-09-08), United Kingdom, pages 984 - 994, XP093055754, ISSN: 0105-4538, Retrieved from the Internet <URL:https://onlinelibrary.wiley.com/doi/full-xml/10.1111/all.15491> DOI: 10.1111/all.15491 *
NIKOLOVSKI ET AL., J INVEST DERMATOL, vol. 128, 2008, pages 1728 - 1736
NOWICKI ET AL.: "News about Emollients with Rhealba Oat Plantlets Extract: Prevention and Treatment of Atopic Dermatitis", J CLIN PEDIATR NEONATAL CARE, vol. 6, no. 2, 2019, pages 021
O' REGAN GMKEMPERMAN PMSANDI LANDS ACHEN HCAMPBELL LEKROBOTH KWATSON RROWLAND MPUPPELS GJMCLEAN WH: "Raman profiles of the stratum corneum define 3 filaggrin genotype-determined atopic dermatitis endophenotypes", J ALLERGY CLIN IMMUNOL, vol. 126, no. 3, 2010, pages 574 - 80
PERKIN MRLOGAN KMARRS TRADULOVIC SCRAVEN JBOYLE RJCHALMERS JRWILLIAMS HCVERSTEEG SAVAN REE R: "Association of frequent moisturizer use in early infancy with the development of food allergy", JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, vol. 147, 3 March 2021 (2021-03-03), pages 967 - 976
RING J.: "Atopic Dermatitis", 2016, SPRINGER, article "Pathophysiology of Atopic Dermatitis/Eczema"
SI MIN NG ET AL.: "Moisturisers from birth in at-risk infants of atopic dermatitis - a pragmatic randomised controlled trial", AUSTRALASIAN JOURNAL OF DERMATOLOGY, vol. 62, 2021, pages e539 - e545
SIMPSON E L ET AL: "A pilot study of emollient therapy for the primary prevention of atopic dermatitis", JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, MOSBY, INC, US, vol. 63, no. 4, 1 October 2010 (2010-10-01), pages 587 - 593, XP027375587, ISSN: 0190-9622, [retrieved on 20100807] *
SIMPSON ELCHALMERS JRHANIFIN JMTHOMAS KSCORK, MJMCLEAN WHBROWN SJCHEN ZCHEN YWILLIAMS HC: "Emollient enhancement of the skin barrier from birth offers effect atopic dermatitis prevention", J ALLERGY CLIN IMMUNOL, vol. 134, no. 4, 2014, pages 818 - 23
SKJERVEN ET AL.: "Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial", LANCET, vol. 395, no. 10228, 19 February 2020 (2020-02-19), pages 951 - 961, XP086100137, DOI: 10.1016/S0140-6736(19)32983-6
SKJERVEN HOREHBINDER EMVETTUKATTIL RGRANUM VHAUGEN GHEDLIN GLANDR LMARSLAND BJRUDI KSJOBORG KD ET AL.: "Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial", LANCET 2020, vol. 385, no. 10228, 2020, pages 951 - 961, XP086100137, DOI: 10.1016/S0140-6736(19)32983-6
STAMATAS ET AL., DERMATOL, vol. 27, 2010, pages 125 - 131
TECHASATIAN ET AL.: "Effects of an emollient application on newborn skin from birth for prevention of atopic dermatitis: A randomized controlled study in Thai neonates", JEADV, vol. 36, 21 September 2021 (2021-09-21), pages 76 - 83
TELOFSKI ET AL., DERMATOL RES PRACT, 2012, pages 198789
WILLIAMS ET AL.: "UK Working Party Diagnostic Criteria", BR J DERMATOL, vol. 131, no. 3, September 1994 (1994-09-01), pages 406 - 16

Similar Documents

Publication Publication Date Title
Varothai et al. Moisturizers for patients with atopic dermatitis
US7700110B2 (en) Skin firming and lifting compositions and methods of use
US11311596B2 (en) Active ingredient obtained from Ophiopogon japonicus for the treatment of atopic dermatitis
WO2008140200A1 (fr) Compositions externes pour la peau
KR102623994B1 (ko) 건선, 아토피성 피부염, 만성 두드러기, 항히스타민-내성 가려움증 및 노인성 가려움증의 치료를 위한 암보라 추출물 및 녹차 추출물을 포함하는 조성물
CN109431914B (zh) 头皮养护组合物及其应用
US20180289754A1 (en) Composition containing lactic acid bacteria and its use to treat atopic dermatitis
US20150118334A1 (en) Topical compositions for the treatment of chronic inflammatory skin disease
CN113599319B (zh) 一种婴幼儿多效护理化妆品组合物
CN110623899A (zh) 一种大米来源的护肤组合物及其制备方法
EP2494973A1 (fr) Compositions topiques pour le traitement et la prévention de maladies de la peau, en particulier de la radiodermite provoquée par un rayonnement ionisant
US20230309921A1 (en) Window of Opportunity Skin Treatment Regimen and Composition for Preventing the Onset of or Treating Atopic Dermatitis
KR102149851B1 (ko) 염증성 피부 질환 개선을 위한 소듐서팩틴의 신규 용도
CN108721154B (zh) 一种用于皮肤保湿和屏障修复的护肤品及其制备方法
WO2023194839A1 (fr) Fenêtre de schéma thérapeutique cutané d&#39;opportunité et composition pour prévenir l&#39;apparition de la dermatite atopique ou pour traiter celle-ci
Fitzner et al. Investigating the effect of the pH of foot care product formulations on pedal skin in diabetic and non‐diabetic subjects
KR20110024573A (ko) 소루쟁이 추출물을 이용한 아토피 피부 개선용 화장료 조성물
JP2024504628A (ja) カンナビジオール及びブロッコリー種子油を含有する組成物、並びにそのような組成物の作製方法及び使用方法
KR102623461B1 (ko) 알레르기성 피부 질환 또는 피부 소양증의 예방 또는 치료용 약학 조성물
CN115337216B (zh) 一种具有舒缓功效的护肤品组合及其制备
Pal et al. Review literature on Anti-Dandruff Shampoo
Giannini et al. Tau-Marin Mucoadhesive Gel for Prevention and Treatment of Periodontal Diseases
Matysiak et al. STUDIES ON THE FORMULATION AND FUNCTIONALITY OF AN INNOVATIVE LINE OF TOPICAL PRODUCTS FOR ATOPIC SKIN.
FR3046353A1 (fr) Extrait de cassia alata contre la peau seche a tendance atopique
Kedia To compare efficacy of Mulethi and Guava leaf extract gels in treatment of Localized Aggressive Periodontitis

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23715958

Country of ref document: EP

Kind code of ref document: A1